2016
Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials
Giustino G, Mehran R, Bansilal S, Feit F, Lincoff M, Deliargyris EN, Kirtane AJ, Généreux P, Redfors B, Prats J, Bernstein D, Brener SJ, Skerjanec S, Lansky AJ, Francese DP, Dangas GD, Stone GW. Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. The American Journal Of Cardiology 2016, 118: 6-16. PMID: 27181566, DOI: 10.1016/j.amjcard.2016.04.005.Peer-Reviewed Original ResearchConceptsGlycoprotein IIb/IIIa inhibitorsPercutaneous coronary interventionMajor adverse cardiac eventsEfficacy of bivalirudinAdverse cardiac eventsDiabetes mellitusMajor bleedingCoronary interventionBivalirudin treatmentCause mortalityCardiac eventsNon-coronary artery bypass graft-related major bleedingPrimary efficacy end pointPrimary safety end pointUrgent Intervention Triage StrategyAcute Myocardial Infarction trialIIb/IIIa inhibitorsEnd pointHORIZONS-AMI trialPCI Linking AngiomaxComposite of deathEfficacy end pointMyocardial Infarction trialSafety end pointPatient-level data
2012
Strategies for Multivessel Revascularization in Patients with Diabetes
Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S, Bertrand M, Fuster V. Strategies for Multivessel Revascularization in Patients with Diabetes. New England Journal Of Medicine 2012, 367: 2375-2384. PMID: 23121323, DOI: 10.1056/nejmoa1211585.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionCoronary artery diseaseMultivessel coronary artery diseaseDrug-eluting stentsCABG groupPCI groupArtery diseaseMyocardial infarctionMedical therapyMean ageAdvanced coronary artery diseaseLow-density lipoprotein cholesterolAggressive medical therapyBenefit of CABGComposite of deathCoronary artery bypassNonfatal myocardial infarctionPatients' mean ageThree-vessel diseaseSystolic blood pressurePrimary outcome measureRate of deathMultivessel revascularizationNonfatal strokeCoronary intervention
2011
Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R. Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 1011-1019. PMID: 21939942, DOI: 10.1016/j.jcin.2011.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsChi-Square DistributionChronic DiseaseDrug-Eluting StentsEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansIsraelKaplan-Meier EstimateKidney DiseasesMaleMetalsMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsProspective StudiesProsthesis DesignRecombinant ProteinsRecurrenceRisk AssessmentRisk FactorsStentsStrokeThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionNet adverse cardiac eventsChronic kidney diseasePercutaneous coronary interventionTarget vessel revascularizationBare metal stentsDrug-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingBivalirudin monotherapyCoronary interventionKidney diseaseMyocardial infarctionRate of TVRIschemia-driven target vessel revascularizationNon-coronary artery bypassIIb/IIIa inhibitorsBenefit of bivalirudinDifferent antithrombotic strategiesAdverse cardiac eventsComposite of deathHigh rate
2009
5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation Insights From a Patient-Level Pooled Analysis of 4 Randomized Trials Comparing Sirolimus-Eluting Stents With Bare-Metal Stents
Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, Popma JJ, Parise H, Fahy M, Mehran R. 5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation Insights From a Patient-Level Pooled Analysis of 4 Randomized Trials Comparing Sirolimus-Eluting Stents With Bare-Metal Stents. Journal Of The American College Of Cardiology 2009, 54: 894-902. PMID: 19712798, DOI: 10.1016/j.jacc.2009.04.077.Peer-Reviewed Original ResearchConceptsBare metal stentsTarget vessel revascularizationStent thrombosisRate of deathMyocardial infarctionVessel revascularizationPooled analysisAcademic Research Consortium definitionsPatient-level pooled analysisDrug-eluting stent implantationArterial healing responseComposite of deathProbable stent thrombosisLong-term safetyDrug-eluting stentsLate stent thrombosisClinical outcomesRandomized trialsStent implantationSuperior efficacyBMS groupThrombosisHealing responseSES groupStents9-Month Clinical, Angiographic, and Intravascular Ultrasound Results of a Prospective Evaluation of the Axxess Self-Expanding Biolimus A9-Eluting Stent in Coronary Bifurcation Lesions The DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) Study
Verheye S, Agostoni P, Dubois CL, Dens J, Ormiston J, Worthley S, Trauthen B, Hasegawa T, Koo BK, Fitzgerald PJ, Mehran R, Lansky AJ. 9-Month Clinical, Angiographic, and Intravascular Ultrasound Results of a Prospective Evaluation of the Axxess Self-Expanding Biolimus A9-Eluting Stent in Coronary Bifurcation Lesions The DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) Study. Journal Of The American College Of Cardiology 2009, 53: 1031-1039. PMID: 19298915, DOI: 10.1016/j.jacc.2008.12.012.Peer-Reviewed Original ResearchConceptsPercent neointimal volume obstructionMajor adverse cardiac eventsNeointimal volume obstructionCoronary bifurcation lesionsBifurcation lesionsAXXESS stentVolume obstructionMulticenter studyMyocardial infarctionLate lossParent vesselDe novo bifurcation lesionsEnd pointIntravascular ultrasound resultsNovo bifurcation lesionsAdverse cardiac eventsComposite of deathPrimary end pointSecondary end pointsProspective multicenter studySirolimus-eluting stentsAdverse late outcomesSide branchesDrug-eluting stentsLate stent thrombosis
2004
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale
Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, Lansky AJ, Lincoff AM, Mehran R, Moses JW, Ohman M, White HD. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale. American Heart Journal 2004, 148: 764-775. PMID: 15523305, DOI: 10.1016/j.ahj.2004.04.036.Peer-Reviewed Original ResearchMeSH KeywordsAngina, UnstableAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsCardiac CatheterizationCombined Modality TherapyCoronary Artery BypassEnoxaparinHeparinHirudinsHumansMulticenter Studies as TopicMyocardial InfarctionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRandomized Controlled Trials as TopicRecombinant ProteinsResearch DesignConceptsIIb/IIIa inhibitionUrgent Intervention Triage Strategy (ACUITY) trialIIb/IIIa inhibitorsAcute CatheterizationInhibitor administrationStrategy trialMyocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary study end pointAdverse ischemic eventsHigh-risk ACSComposite of deathStudy end pointAcute coronary syndromeHigh-risk patientsSurgical revascularization proceduresTreatment of choiceSecond random assignmentACUITY trialMajor bleedingSurgical revascularizationUnplanned revascularizationCoronary syndromeEarly angiographyIschemic events
2002
Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction
Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ. Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction. New England Journal Of Medicine 2002, 346: 957-966. PMID: 11919304, DOI: 10.1056/nejmoa013404.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCombined Modality TherapyCoronary AngiographyFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionMyocardial ReperfusionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecurrenceStentsStrokeConceptsPrimary percutaneous transluminal coronary angioplastyAcute myocardial infarctionPercent of patientsPrimary end pointInfarct-related arteryRate of deathMyocardial infarctionAbciximab therapyReperfusion strategyPlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsTarget vesselIIb/IIIa inhibitorsPercutaneous transluminal coronary angioplastyEnd pointComposite of deathTarget vessel revascularizationIschemia-driven revascularizationTransluminal coronary angioplastyComparison of AngioplastyAbciximab useRecurrent ischemiaExperienced centersCoronary angioplastyCoronary stenting
2001
Localized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of Restenosis after Stenting
Leon M, Teirstein P, Moses J, Tripuraneni P, Lansky A, Jani S, Wong S, Fish D, Ellis S, Holmes D, Kerieakes D, Kuntz R. Localized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of Restenosis after Stenting. New England Journal Of Medicine 2001, 344: 250-256. PMID: 11172151, DOI: 10.1056/nejm200101253440402.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryBrachytherapyCombined Modality TherapyCoronary DiseaseCoronary ThrombosisDose-Response Relationship, RadiationDouble-Blind MethodFemaleGamma RaysHumansIridium RadioisotopesMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPlatelet Aggregation InhibitorsRadiotherapy DosageSecondary PreventionStentsConceptsIridium-192 groupMyocardial infarctionLate thrombosisStent restenosisIridium-192Intracoronary irradiationTarget lesionsIntracoronary gamma radiation therapyMajor adverse cardiac eventsFrequency of restenosisOral antiplatelet therapyAdverse cardiac eventsComposite of deathPrimary end pointLate myocardial infarctionIntracoronary radiation therapyIncidence of deathRecurrence of restenosisGamma radiation therapyEligible patientsAngiographic restenosisAntiplatelet therapyPlacebo groupCardiac eventsCoronary angioplasty